Youssef W Naguib

List of Publications by Year
in descending order

33	816	567144 15	501076 28
papers	citations	h-index	g-index

33	33	33	1495
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HPLC-UV Method Validation for Amobarbital and Pharmaceutical Stability Evaluation When Dispersed in a Hyaluronic Acid Hydrogel: A New Concept for Post-Traumatic Osteoarthritis Prevention. Journal of Pharmaceutical Sciences, 2022, 111, 1379-1390.	1.6	1
2	The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-coated PLGA-PEG nanoparticles. Drug Delivery and Translational Research, 2022, 12, 1684-1696.	3.0	5
3	Surface Modification of Nanoparticles Enhances Drug Delivery to the Brain and Improves Survival in a Glioblastoma Multiforme Murine Model. Bioconjugate Chemistry, 2022, 33, 1957-1972.	1.8	10
4	An injectable microparticle formulation for the sustained release of the specific MEK inhibitor PD98059: in vitro evaluation and pharmacokinetics. Drug Delivery and Translational Research, 2021, 11, 182-191.	3.0	9
5	Preformulation-Assisted Design and Characterization of Modified Release Gastroretentive Floating Extrudates Towards Improved Bioavailability and Minimized Side Effects of Baclofen. Journal of Pharmaceutical Sciences, 2021, 110, 1227-1239.	1.6	5
6	Thiophene Derivativeâ€Loaded Nanoparticles Mediate Anticancer Activity Through the Inhibition of Kinases and Microtubule Assembly. Advanced Therapeutics, 2021, 4, 2100058.	1.6	7
7	Effect of surface mannosylation on the cytotoxicity and cellular uptake of stearoyl gemcitabine-incorporated, acid-sensitive micelles. Colloids and Interface Science Communications, 2021, 43, 100441.	2.0	0
8	Solubilized ubiquinol for preserving corneal function. Biomaterials, 2021, 275, 120842.	5.7	13
9	Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAFV600E melanoma-bearing mice. International Journal of Pharmaceutics, 2021, 606, 120876.	2.6	12
10	An Injectable Microparticle Formulation Provides Long-Term Inhibition of Hypothalamic ERK1/2 Activity and Sympathetic Excitation in Rats with Heart Failure. Molecular Pharmaceutics, 2020, 17, 3643-3648.	2.3	4
11	Ubiquinol Supplementation of Donor Tissue Enhances Corneal Endothelial Cell Mitochondrial Respiration. Cornea, 2020, 39, 1285-1290.	0.9	3
12	Design, characterization and in vivo evaluation of modified release baclofen floating coated beads. International Journal of Pharmaceutics, 2020, 582, 119344.	2.6	6
13	Modified Spraying Technique and Response Surface Methodology for the Preparation and Optimization of Propolis Liposomes of Enhanced Anti-Proliferative Activity against Human Melanoma Cell Line A375. Pharmaceutics, 2019, 11, 558.	2.0	35
14	Synthesis, structure, and biological evaluation of a platinumâ€carbazole conjugate. Chemical Biology and Drug Design, 2018, 91, 116-125.	1.5	3
15	Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics. AAPS Journal, 2018, 20, 108.	2.2	67
16	Reverse Microemulsion-Based Synthesis of (Bis)phosphonateâ€“Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acidâ€“Calcium Complexes. ACS Applied Materials & Interfaces, 2017, 9, 14478-14489.	4.0	19
17	Acid-Sensitive Sheddable PEGylated, Mannose-Modified Nanoparticles Increase the Delivery of Betamethasone to Chronic Inflammation Sites in a Mouse Model. Molecular Pharmaceutics, 2017, 14, 1929-1937.	2.3	14
18	In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method. International Journal of Pharmaceutics, 2017, 526, 69-76.	2.6	27

#	Article	IF	Citations
19	Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2Â´, 2Â´-Difluorodeoxycytidine (DHA-dFdC). Pharmaceutical Research, 2017, 34, 1224-1232.	1.7	3
20	A method to improve the efficacy of topical eflornithine hydrochloride cream. Drug Delivery, 2016, 23, 1-7.	2.5	32
21	Injectable Formulations of Poorly Water-Soluble Drugs. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 257-293.	0.2	1
22	Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2â€², 2â€²-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity. Neoplasia, 2016, 18, 33-48.	2.3	14
23	Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer. Molecular Pharmaceutics, 2016, 13, 1833-1842.	2.3	65
24	Acid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-Î± siRNA in Chronic Inflammation Sites. Molecular Therapy - Nucleic Acids, 2016, 5, e340.	2.3	37
25	Applications of bacillus Calmetteâ€“Guerin and recombinant bacillus Calmetteâ€“Guerin in vaccine development and tumor immunotherapy. Expert Review of Vaccines, 2015, 14, 1255-1275.	2.0	43
26	Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Expert Review of Vaccines, 2015, 14, 1255-75.	2.0	24
27	Nanomedicine: The Promise and Challenges in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, 2014, 811, 207-233.	0.8	19
28	The effect of microneedles on the skin permeability and antitumor activity of topical 5-fluorouracil. Acta Pharmaceutica Sinica B, 2014, 4, 94-99.	5.7	68
29	Biodistribution and in Vivo Activities of Tumor-Associated Macrophage-Targeting Nanoparticles Incorporated with Doxorubicin. Molecular Pharmaceutics, 2014, 11, 4425-4436.	2.3	86
30	Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and in Vivo Evaluation. Molecular Pharmaceutics, 2014, 11, 1239-1249.	2.3	90
31	Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer. Colloids and Surfaces B: Biointerfaces, 2012, 94, 274-280.	2.5	59
32	Prednisolone-Loaded PLGA Microspheres. In Vitro Characterization and In Vivo Application in Adjuvant-Induced Arthritis in Mice. AAPS PharmSciTech, 2010, 11, 859-869.	1.5	34
33	CONTROLLED-RELEASE PREDNISOLONE POLY (DL-LACTIDE) MICROSPHERES: IMPACT OF FORMULATION PARAMETERS, CHARACTERIZATION AND RELEASE MECHANISM. Bulletin of Pharmaceutical Sciences, 2008, 31, 49-67.	0.0	1